目次

Table of Content

Chapter 1 Research Methodology
1.1 Market Segmentation & Scope
1.1.1 Regional Scope
1.1.2 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.2 Volume Price Analysis (Model 2)
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives

Chapter 2 Executive Summary
2.1 Market Outlook

Chapter 3 Oncology-Based In-vivo CRO Market: Variables, Trends, & Scope
3.1 Segment Outlook
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Accelerating the time to market
3.2.1.2 Economic efficiency
3.2.1.3 Increasing mergers and collaborations
3.2.1.4 Increasing outsourcing of R&D Activities
3.2.2 Market Restraint Analysis
3.2.2.1 Quality issues with CRO
3.2.2.2 Presence of suitable alternative
3.3 Oncology In-vivo CRO Market Analysis Tools
3.3.1 Porter’s Five Forces Analysis
3.3.2 PESTEL Analysis

Chapter 4 Oncology-Based in-vivo CRO Market: Indication Estimates & Trend Analysis
4.1 Oncology-Based in-vivo CRO Market: Indication Movement Analysis
4.2 Blood cancer
4.2.1 Blood cancer market estimates and forecasts, 2018 - 2030 (USD Million)
4.2.1.1 Syngeneic model based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
4.2.1.2 PDX-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
4.2.1.3 Xenograft-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
4.3 Solid tumors
4.3.1 Solid tumors market estimates and forecasts, 2018 - 2030 (USD Million)
4.3.1.1 Syngeneic model based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
4.3.1.2 PDX-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
4.3.1.3 Xenograft-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
4.4 Others
4.4.1 Other market estimates and forecasts, 2018 - 2030 (USD Million)
4.4.1.1 Syngeneic model based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
4.4.1.2 PDX-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
4.4.1.3 Xenograft-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5 Oncology-Based in-vivo CRO Market: Regional Estimates & Trend Analysis, by Indication
5.1 Oncology-Based in-vivo CRO Market Share by Region, 2022 & 2030
5.2 North America
5.2.1 North America Oncology-Based in-vivo CRO market estimates and forecasts, 2018 - 2030
5.2.2 U.S.
5.2.2.1 U.S. Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
5.2.3 Canada
5.2.3.1 Canada Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
5.3 Europe
5.3.1 Europe Oncology-Based in-vivo CRO market estimates and forecasts, 2018 - 2030
5.3.2 U.K.
5.3.2.1 U.K. Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
5.3.3 Germany
5.3.3.1 Germany Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
5.3.4 France
5.3.4.1 France Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
5.3.5 Italy
5.3.5.1 Italy Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
5.3.6 Spain
5.3.6.1 Spain Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
5.3.7 Norway
5.3.7.1 Norway Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
5.3.8 Sweden
5.3.8.1 Sweden Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
5.3.9 Denmark
5.3.9.1 Denmark Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
5.4 Asia Pacific
5.4.1 Asia Pacific Oncology-Based in-vivo CRO market estimates and forecasts, 2018 - 2030
5.4.2 Japan
5.4.2.1 Japan Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
5.4.3 China
5.4.3.1 China Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
5.4.4 India
5.4.4.1 India Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
5.4.5 Australia
5.4.5.1 Australia Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
5.4.6 Thailand
5.4.6.1 Thailand Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
5.4.7 South Korea
5.4.7.1 South Korea Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
5.5 Latin America
5.5.1 Latin America Oncology-Based in-vivo CRO market estimates and forecasts, 2018 - 2030
5.5.2 Brazil
5.5.2.1 Brazil Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
5.5.3 Argentina
5.5.3.1 Argentina Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
5.5.4 Mexico
5.5.4.1 Mexico Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
5.6 MEA
5.6.1 MEA Oncology-Based in-vivo CRO market estimates and forecasts, 2018 - 2030
5.6.2 South Africa
5.6.2.1 South Africa Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
5.6.3 Saudi Arabia
5.6.3.1 Saudi Arabia Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
5.6.4 UAE
5.6.4.1 UAE Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)
5.6.5 Kuwait
5.6.5.1 Kuwait Oncology-Based in-vivo CRO market estimates and forecasts, by indication, 2018 - 2030 (USD Million)

Chapter 6 Competitive Landscape
6.1 Strategy Framework
6.2 Company Profiles
6.2.1 Charles River Laboratory (CRL)
6.2.1.1 Company overview
6.2.1.2 Financial performance
6.2.1.3 Product benchmarking
6.2.1.4 Strategic initiatives
6.2.2 ICON Plc
6.2.2.1 Company overview
6.2.2.2 Financial performance
6.2.2.3 Product benchmarking
6.2.2.4 Strategic initiatives
6.2.3 Thermo Fisher Scientific Inc.
6.2.3.1 Company overview
6.2.3.2 Financial performance
6.2.3.3 Service benchmarking
6.2.3.4 Strategic initiatives
6.2.4 Eurofins Scientific
6.2.4.1 Company overview
6.2.4.2 Financial performance
6.2.4.3 Product benchmarking
6.2.4.4 Strategic initiatives
6.2.5 Taconic Biosciences
6.2.5.1 Company overview
6.2.5.2 Financial performance
6.2.5.4 Product benchmarking
6.2.5.5 Strategic initiatives
6.2.6 Crown Bioscience
6.2.6.1 Company overview
6.2.6.2 Financial performance
6.2.6.3 Product benchmarking
6.2.6.4 Strategic initiatives
6.2.7 Lab Corp
6.2.7.1 Company overview
6.2.7.2 Financial performance
6.2.7.3 Product benchmarking
6.2.7.4 Strategic initiatives
6.2.8 WuXi AppTec
6.2.8.1 Company overview
6.2.8.2 Financial performance
6.2.8.4 Product benchmarking
6.2.8.5 Strategic Initiatives
6.2.9 EVOTEC
6.2.9.1 Company overview
6.2.9.2 Financial performance
6.2.9.3 Product benchmarking
6.2.9.4 Strategic initiatives
6.2.10 The Jackson Laboratory
6.2.10.1 Company overview
6.2.10.2 Financial performance
6.2.10.4 Product benchmarking
6.2.10.5 Strategic initiatives

List of Tables
Table 1 List of secondary sources
Table 2 List of Abbreviations

List of Figures
Fig. 1 Market summary
Fig. 2 Market trends & outlook
Fig. 3 Market segmentation & scope
Fig. 4 Market driver relevance analysis (Current & future impact)
Fig. 5 Pharmaceutical R&D spending, 2007 - 2012 (USD Billion)
Fig. 6 Market restraint relevance analysis (Current & future impact)
Fig. 7 Penetration & growth prospect mapping
Fig. 8 SWOT Analysis, By Factor (political & legal, economic and social)
Fig. 9 Porter’s Five Forces Analysis
Fig. 10 Oncology-Based in-vivo CRO market indication outlook key takeaways
Fig. 11 Oncology-Based in-vivo CRO market: Indication movement analysis
Fig. 12 Global blood cancer market, 2018 - 2030 (USD Million)
Fig. 13 Global syngeneic model-based blood cancer market, 2018 - 2030 (USD Million)
Fig. 14 Global PDX model-based blood cancer market, 2018 - 2030 (USD Million)
Fig. 15 Global xenograft-based blood cancer market, 2018 - 2030 (USD Million)
Fig. 16 Global solid tumor market, 2018 - 2030 (USD Million)
Fig. 17 Global syngeneic model-based solid tumor market, 2018 - 2030 (USD Million)
Fig. 18 Global PDX model-based solid tumor market, 2018 - 2030 (USD Million)
Fig. 19 Global xenograft-based solid tumor market, 2018 - 2030 (USD Million)
Fig. 20 Global other cancers market, 2018 - 2030 (USD Million)
Fig. 21 Global syngeneic model-based other cancers market, 2018 - 2030 (USD Million)
Fig. 22 Global PDX model-based other cancers market, 2018 - 2030 (USD Million)
Fig. 23 Global xenograft-based other cancers market, 2018 - 2030 (USD Million)
Fig. 24 Regional marketplace: Key takeaways
Fig. 25 Regional outlook, 2022 & 2030
Fig. 26 North America Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 27 U.S. Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 28 Canada Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 29 Europe in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 30 U.K. Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 31 Germany Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 32 France Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 33 Italy Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 34 Spain Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 35 Norway Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 36 Sweden Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 37 Denmark Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 38 Asia Pacific Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 39 Japan oncology-based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 40 China oncology-based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 41 India Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 42 Australia Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 43 Thailand Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 44 South Korea Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 45 Latin America Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 46 Brazil Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 47 Argentina Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 48 Mexico Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 49 MEA Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 50 South Africa Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 51 Saudi Arabia Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 52 UAE Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)
Fig. 53 Kuwait Oncology-Based in-vivo CRO market, 2018 - 2030 (USD Million)